<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39396750</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0712</ISSN><JournalIssue CitedMedium="Internet"><Volume>984</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>European journal of pharmacology</Title><ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Captopril inhibits the overproduction of proopiomelanocortin and adrenocorticotropic hormone in the pituitary gland of male diabetic mice in close relationship with an increase in glucocorticoid receptor expression.</ArticleTitle><Pagination><StartPage>177057</StartPage><MedlinePgn>177057</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejphar.2024.177057</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0014-2999(24)00747-7</ELocationID><Abstract><AbstractText>Prior investigation shows that diabetic patients present hypothalamus-pituitary-adrenal (HPA) axis hyperactivity related to impaired negative feedback. This study investigates the effect of Captopril on the overproduction of adrenocorticotropic hormone (ACTH) and its precursor proopiomelanocortin (POMC) in the pituitary gland of male diabetic mice. Diabetes was induced by intravenous injection of alloxan into fasted Swiss-webster mice, and the animals were treated with Captopril for 14 consecutive days, starting 7 days post-diabetes induction. Plasma corticosterone levels were evaluated by ELISA, while pituitary gland expressions of angiotensin-II type 1 receptor (AT<sub>1</sub>), angiotensin-II type 2 receptor (AT<sub>2</sub>), ACTH, Bax, Bcl-2, KI-67, POMC, and glucocorticoid receptor (GR) were evaluated using immunohistochemistry or Western blot. Diabetic mice showed pituitary gland overexpression of AT<sub>1</sub>, without altering AT<sub>2</sub> levels, which were sensitive to Captopril treatment. Furthermore, diabetic mice presented hypercortisolism, along with an increase in the number of corticotroph cells, POMC and ACTH expression, and number of proliferative cells, and a decrease of GR expression in the pituitary gland. In addition, treatment with Captopril reduced systemic corticosterone levels, corticotroph and proliferative cell numbers, and Bcl-2, POMC, and ACTH expression in the pituitary gland of diabetic mice, besides increasing the expression of Bax and GR. In conclusion, these findings show that Captopril is a promising therapy for treating complications associated with HPA axis hyperactivity in diabetic patients, in a mechanism probably related to the downregulation of POMC production in the pituitary gland and subsequent reduction of systemic corticosterone levels.</AbstractText><CopyrightInformation>Copyright © 2024 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chaves</LastName><ForeName>Amanda da Silva</ForeName><Initials>ADS</Initials><AffiliationInfo><Affiliation>Laboratório de Inflamação, Centro de Pesquisa, Inovação e Vigilância em COVID-19 e Emergências Sanitárias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, nº 4036, Manguinhos, CEP 21040-361, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magalhães</LastName><ForeName>Nathalia Santos</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Laboratório de Inflamação, Centro de Pesquisa, Inovação e Vigilância em COVID-19 e Emergências Sanitárias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, nº 4036, Manguinhos, CEP 21040-361, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Insuela</LastName><ForeName>Daniella Bianchi Reis</ForeName><Initials>DBR</Initials><AffiliationInfo><Affiliation>Laboratório de Inflamação, Centro de Pesquisa, Inovação e Vigilância em COVID-19 e Emergências Sanitárias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, nº 4036, Manguinhos, CEP 21040-361, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Patrícia Machado Rodrigues E</ForeName><Initials>PMRE</Initials><AffiliationInfo><Affiliation>Laboratório de Inflamação, Centro de Pesquisa, Inovação e Vigilância em COVID-19 e Emergências Sanitárias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, nº 4036, Manguinhos, CEP 21040-361, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Marco Aurélio</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Laboratório de Inflamação, Centro de Pesquisa, Inovação e Vigilância em COVID-19 e Emergências Sanitárias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, nº 4036, Manguinhos, CEP 21040-361, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Vinicius Frias</ForeName><Initials>VF</Initials><AffiliationInfo><Affiliation>Laboratório de Inflamação, Centro de Pesquisa, Inovação e Vigilância em COVID-19 e Emergências Sanitárias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, nº 4036, Manguinhos, CEP 21040-361, Rio de Janeiro, Brazil; Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação (INCT-NIM), Brazil. Electronic address: vinicius.frias@fiocruz.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharmacol</MedlineTA><NlmUniqueID>1254354</NlmUniqueID><ISSNLinking>0014-2999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin II(1)</Keyword><Keyword MajorTopicYN="N">Captopril</Keyword><Keyword MajorTopicYN="N">Glucocorticoid receptor(3)</Keyword><Keyword MajorTopicYN="N">HPA axis(4)</Keyword><Keyword MajorTopicYN="N">POMC(5)</Keyword><Keyword MajorTopicYN="N">diabetes(2)</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39396750</ArticleId><ArticleId IdType="doi">10.1016/j.ejphar.2024.177057</ArticleId><ArticleId IdType="pii">S0014-2999(24)00747-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle>